← Back to all signals
RESEARCH PAPER ANALYSIS

Serum albumin and uric acid: biomarkers of neurocognitive and physical function in early Parkinson's disease.

In 48 early PD patients, higher normal-range serum uric acid and albumin were associated with lower motor severity, faster reaction times, better mobility, and ERP signs of more efficient neural processing, with UA showing a linear protective trend and albumin an inverted-U relationship with…

PMID41995808
JournalExperimental brain research
Publication Date2026-04-17
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

In 48 early PD patients, higher normal-range serum uric acid and albumin were associated with lower motor severity, faster reaction times, better mobility, and ERP signs of more efficient neural processing, with UA showing a linear protective trend and albumin an inverted-U relationship with…

WHY IT MATTERS

Research significance

Uric acid and albumin are readily measured systemic biomarkers that may index metabolic reserve and help stratify patients or motivate targeted metabolic/antioxidant interventions in neuroprotective trials, although the cross-sectional design and small sample limit causal inference.

ABSTRACT

Source abstract

Serum albumin and uric acid (UA), both recognized for their antioxidant properties, have been linked to Parkinson’s disease (PD) progression. However, their associations with neurocognitive performance and physical fitness in early-stage PD remain unclear. To examine relationships between albumin and UA with cognitive performance, neurophysiological indices, and physical function in early-stage PD. Forty-eight individuals with early-stage PD were stratified into high and low groups based on median serum albumin and UA levels. Supplementary regression analyses examined dose-response associations. Neurocognitive performance was assessed via a working memory task with event-related potential (ERP) recordings. Physical fitness measures included cardiorespiratory fitness, muscle strength, and the 8-foot Timed Up-and-Go (TUG) test. Group comparisons used repeated-measures analysis of variance (ANOVA) and nonparametric tests. Higher albumin and UA levels were associated with lower motor severity; higher UA also linked to better global cognition. Both high-level groups showed faster reaction times. ERP analysis revealed higher UA associated with more negative N2 and smaller P3 amplitudes, suggesting efficient conflict monitoring and attentional processing. Both groups performed better on TUG, while only high albumin showed superior cardiorespiratory fitness. Regression models revealed a consistent linear protective trend for UA, whereas albumin exhibited an inverted U-shaped relationship with global cognition. Higher serum albumin and UA levels within the normal range are associated with superior neural efficiency and functional mobility in early-stage PD. These biomarkers may reflect systemic metabolic reserve associated with motor and cognitive function in early-stage PD.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic